Credit rating agency, Indian Ratings and Research has assigned a short term rating of ‘A1+’ to Wockhardt’s proposed Rs 1 billion commercial paper (CP)/short-term debt programme .
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.